At 9.0% CAGR, the Europe Newborn Screening Market is Projected to be Worth US$ 653.83 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Europe newborn screening market was valued at US$ 328.04 in 2022 and is expected to reach US$ 653.83 million by 2030, registering a CAGR of 9.0% from 2022 to 2030. Genetic screening of newborns and surging government funding for newborn screening are among the critical factors attributed to the Europe newborn screening market expansion.

The demand for comprehensive genetic screening of newborns is rising with the deepening knowledge about the genetic causes of medical conditions and advancements in healthcare technologies. As a result, companies in the newborn screening market are developing innovative, cost-effective screening solutions. Yescarta and Zynteglo are two more examples of authorized gene treatments for large B-cell lymphoma and beta-thalassemia. Further, the emergence of technologies conferring an ability to identify genetic predispositions to diseases at birth pave the way for personalized healthcare, aligning with the broader trend of precision medicine.

Screening for genetic diseases during pregnancy also focuses on the early detection of pregnancy-related problems. Next-generation sequencing aids in the prenatal screening of neonates with a sensitivity of above 95% for detecting aneuploidies (such as Down syndrome and Trisomy 21) or partial chromosomal abnormalities (duplications or deletions) in all chromosomes. Fluorescence in-situ hybridization (FISH) is employed to detect monogenic illnesses such as sickle cell anemia; it also aids in an effective preimplantation genetic diagnosis. Noninvasive procedures such as the cell-free fetal DNA approach using maternal plasma are the recent advancements in genetic tests. The embryonic DNA can be distinguished from maternal DNA pieces based on differences in their sizes. Real-time PCR with fluorescent probes, shotgun sequencing (Solexa or Illumina), or huge targeted parallel sequencing can be used to examine DNA associated with fetal medical conditions. This would allow doctors to provide early molecular interventions with certain pharmacological therapies (pharmacogenetics) and to transform cells, tissues, and organs physically and chemically if this type of genetic screening is further researched. Thus, advancements in methods for screening infants for genetic disorders hold immense potential for the overall newborn screening market.

On the contrary, lack of uniformity in newborn screening policies and practices hampers the growth Europe newborn screening market.

Based on product type, the Europe newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held 74.2% share of the Europe newborn screening market in 2022, amassing US$ 243.45 million. It is projected to garner US$ 519.58 million by 2030 to expand at 9.9% CAGR during 2022-2030. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.

In terms of technology, the Europe newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held 32.7% share of the Europe newborn screening market in 2022, amassing US$ 107.37 million. It is projected to garner US$ 217.89 million by 2030 to expand at 9.2% CAGR during 2022-2030.

Based on test type, the Europe newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held 51.5% share of Europe newborn screening market in 2022, amassing US$ 168.95 million. It is projected to garner US$ 355.19 million by 2030 to expand at 9.7% CAGR during 2022-2030.

By end user, the Europe newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held 65.4% share of Europe newborn screening market in 2022, amassing US$ 214.47 million. It is projected to garner US$ 447.76 million by 2030 to expand at 9.6% CAGR during 2022-2030.

Based on country, the Europe newborn screening market is categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. France held 23.2% share of Europe newborn screening market in 2022, amassing US$ 76.17 million. It is projected to garner US$ 154.60 million by 2030 to expand at 9.3% CAGR during 2022-2030.

Key players operating in the Europe newborn screening market are Bio-Rad Laboratories Inc, Masimo Corp, Medtronic Plc, MRC Holland BV, Natus Medical Inc, PerkinElmer Inc, Waters Corp, and Zentech SA, among others.

- In May 2023, Masimo launched Stork, a revolutionary home baby monitoring system. This innovative system offers parents insights into their baby's health data, helping them learn more about and connect better with their baby. The Masimo Stork baby monitor system comprises several components and is available in multiple configurations. Masimo Stork Vitals+, the flagship solution, consists of a boot with a sensor, video camera, and mobile app.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com